DekaBank Deutsche Girozentrale Trims Stock Position in Humana Inc. $HUM

DekaBank Deutsche Girozentrale cut its position in shares of Humana Inc. (NYSE:HUM) by 2.5% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 55,702 shares of the insurance provider’s stock after selling 1,449 shares during the period. DekaBank Deutsche Girozentrale’s holdings in Humana were worth $13,640,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of the company. Cidel Asset Management Inc. raised its stake in Humana by 13.9% during the second quarter. Cidel Asset Management Inc. now owns 2,429 shares of the insurance provider’s stock worth $594,000 after purchasing an additional 297 shares during the period. Chicago Partners Investment Group LLC lifted its holdings in shares of Humana by 97.1% in the 2nd quarter. Chicago Partners Investment Group LLC now owns 2,560 shares of the insurance provider’s stock worth $607,000 after acquiring an additional 1,261 shares during the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new position in shares of Humana in the 2nd quarter worth approximately $28,164,000. Mutual of America Capital Management LLC boosted its position in shares of Humana by 8.6% during the 2nd quarter. Mutual of America Capital Management LLC now owns 23,206 shares of the insurance provider’s stock worth $5,673,000 after purchasing an additional 1,844 shares during the period. Finally, Chevy Chase Trust Holdings LLC boosted its position in shares of Humana by 0.7% during the 2nd quarter. Chevy Chase Trust Holdings LLC now owns 64,556 shares of the insurance provider’s stock worth $15,783,000 after purchasing an additional 479 shares during the period. 92.38% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

HUM has been the subject of a number of research analyst reports. Wolfe Research increased their price objective on shares of Humana from $283.00 to $313.00 and gave the stock an “outperform” rating in a research report on Monday, October 6th. Guggenheim reaffirmed a “buy” rating on shares of Humana in a research report on Friday, October 3rd. Barclays lowered their price objective on shares of Humana from $315.00 to $245.00 and set an “equal weight” rating for the company in a research report on Friday, October 3rd. Robert W. Baird lowered their price objective on shares of Humana from $300.00 to $297.00 and set a “neutral” rating for the company in a research report on Friday, July 25th. Finally, Bank of America increased their price objective on shares of Humana from $280.00 to $300.00 and gave the stock a “neutral” rating in a research report on Friday, October 10th. Eight investment analysts have rated the stock with a Buy rating, ten have given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, Humana presently has a consensus rating of “Hold” and an average target price of $297.58.

Humana Trading Up 1.2%

Shares of HUM stock opened at $291.14 on Friday. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.95 and a current ratio of 1.95. The stock has a market capitalization of $35.01 billion, a P/E ratio of 22.34, a price-to-earnings-growth ratio of 1.68 and a beta of 0.42. The company has a 50 day moving average price of $281.57 and a 200 day moving average price of $259.05. Humana Inc. has a fifty-two week low of $206.87 and a fifty-two week high of $315.35.

Humana (NYSE:HUM) last posted its quarterly earnings results on Wednesday, July 30th. The insurance provider reported $6.27 EPS for the quarter, missing the consensus estimate of $6.32 by ($0.05). Humana had a return on equity of 13.67% and a net margin of 1.28%.The firm had revenue of $32.39 billion for the quarter, compared to analyst estimates of $31.85 billion. During the same quarter last year, the firm earned $6.96 EPS. The company’s revenue was up 9.6% on a year-over-year basis. Humana has set its FY 2025 guidance at 17.000- EPS. Equities research analysts predict that Humana Inc. will post 16.47 EPS for the current fiscal year.

Humana Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Friday, September 26th will be given a $0.885 dividend. The ex-dividend date is Friday, September 26th. This represents a $3.54 annualized dividend and a yield of 1.2%. Humana’s dividend payout ratio is 27.17%.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.